Abstracts tagged "polymyalgia rheumatica and regulatory cells"

Abstract Number: 1956 • 2014 ACR/ARHP Annual Meeting
Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Gerda Horst³, Abraham Rutgers², Annemieke M.H. Boots⁴ and Elisabeth Brouwer⁵, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Hanzeplein 1, UMCG, Groningen, Netherlands
Background/Purpose: The role of B cells in auto-immunity may extend beyond the production of auto-antibodies. B cells can influence T cell responses via antigen presentation…
Abstract Number: 2349 • 2012 ACR/ARHP Annual Meeting
Corticosterois Therapy Restaured Treg/Th17 Balance in Patients with Polimyalgia Rheumatica
Lorena Alvarez-Rodriguez¹, Marcos Lopez-Hoyos², Jaime Calvo-Alen³, Elena Aurrecoechea⁴, Teresa Ruiz Jimeno⁴, Ignacio Villa⁴, Carmen Gonzalez-Vela⁵ and Victor M. Martinez-Taboada¹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ²Immunology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ³Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ⁵Pathology Anatomy, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain
Background/Purpose: To characterize the levels of circulating T regulatory cells (Tregs) and Th17 cells in polymyalgia rheumatica (PMR). Methods: The study included 46 patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].